ARCHIVES

Study Would Try to Validate EGFR FISH as Predictive Marker for Benefit from Tarceva.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

Vaccine and LDCT Pretreatment Can Help PDACs Become Vulnerable to Immunotherapy

June 27, 2014

Chronobiology Review Still Delayed

May 5, 1989

FDA Advisory Committee Recommends Approval Of Ifosfamide as Third Line Therapy For Testicular Cancer

April 29, 1988

Oral Complications Reduced By Pretherapy NIH Conference Finds

April 28, 1989

CCRAC Shoots Down Two Projects, Approves Others

December 15, 1978

Changes In Clinical Trials Mechanism Inevitable, But NCI Says It will Heed Critics Of Proposals

April 18, 1986